Durvalumab ± Tremelimumab in combination with Platinum based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) - CASPIAN

Study identifier:D419QC00001

ClinicalTrials.gov identifier:NCT03043872

EudraCT identifier:2016-001203-23

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

Medical condition

Small Cell Lung Carcinoma Extensive Disease

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide

Sex

All

Actual Enrollment

987

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 27 Mar 2017
Primary Completion Date: 27 Jan 2020
Estimated Study Completion Date: 29 Mar 2024

Study design

Allocation: Randomized
Endpoint Classification: Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria